Israel Englander’s Verona Pharma VRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-1,796,738
Closed -$192M 6508
2025
Q3
$192M Buy
1,796,738
+1,419,570
+376% +$148M 0.08% 196
2025
Q2
$35.7M Buy
377,168
+53,623
+17% +$3.97M 0.02% 1053
2025
Q1
$20.5M Buy
323,545
+152,097
+89% +$9.1M 0.01% 1482
2024
Q4
$7.96M Buy
171,448
+11,442
+7% +$430K ﹤0.01% 2393
2024
Q3
$4.6M Sell
160,006
-367,634
-70% -$9.05M ﹤0.01% 2910
2024
Q2
$7.63M Buy
527,640
+23,567
+5% +$344K ﹤0.01% 2330
2024
Q1
$8.11M Buy
504,073
+120,722
+31% +$2.09M ﹤0.01% 2392
2023
Q4
$7.62M Sell
383,351
-550,870
-59% -$8.13M ﹤0.01% 2421
2023
Q3
$15.2M Buy
934,221
+400,737
+75% +$7.72M 0.01% 1659
2023
Q2
$11.3M Sell
533,484
-17,278
-3% -$368K 0.01% 1896
2023
Q1
$11.1M Buy
550,762
+236,709
+75% +$5.11M 0.01% 1852
2022
Q4
$8.21M Buy
314,053
+234,713
+296% +$3.13M ﹤0.01% 2346
2022
Q3
$811K Buy
+79,340
New +$669K ﹤0.01% 4517
2022
Q2
Sell
-26,799
Closed -$134K 7549
2022
Q1
$134K Buy
26,799
+10,830
+68% +$63K ﹤0.01% 6019
2021
Q4
$107K Buy
15,969
+1,183
+8% +$6.04K ﹤0.01% 6227
2021
Q3
$81K Buy
+14,786
New +$86K ﹤0.01% 6492
2020
Q4
Sell
-10,942
Closed -$68 5618
2020
Q3
$68 Buy
+10,942
New +$75.6K ﹤0.01% 4276

Other funds holding VRNA

Israel Englander's VRNA Position: Q4 2025 in Review

Israel Englander sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 1,796,738 shares — an estimated $192M sold.

Israel Englander first reported a position in VRNA in Q3 2020 and held it in 17 quarters. The position peaked at $192M in Q3 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

  • Israel Englander reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
  • Israel Englander sold 1,796,738 Verona Pharma shares in Q4 2025, an estimated $192M.
  • Israel Englander first reported a position in Verona Pharma in Q3 2020 and held it in 17 quarters.
  • Israel Englander's Verona Pharma position peaked at $192M in Q3 2025.
  • 1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Millennium Management's 13F filing for Q4 2025, filed 17 Feb 2026.